B-Cell Lymphomas

Common Name(s)

B-Cell Lymphomas

Lymphoma is the most common blood cancer. Lymphocytes are a type of white blood cell that are part of our body’s immune system and help our body fight infections. Lymphoma occurs when these lymphocytes grow and multiply uncontrollably. The body has two main types of lymphocytes, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). B-cell lymphoma occurs when the B-cells in particular grow into lymphomas. The cancerous lymphocyte cells can then travel to various parts of the body including the lymph nodes, blood, spleen, bone marrow and other organs. There are many different types of B-cell lymphomas and the most common type is called diffuse large b-cell lymphoma (DLBCL) which is aggressive (fast-growing) and requires immediate treatment. There are other forms that are slow-growing and respond well to treatment and can go into remission for many years. Genetic factors as well as environmental factors, weak immune system (immunodeficiency due to an organ transplant or HIV/AIDS), drug and chemical exposures, viruses and other unknown factors are thought to play a role in the development of lymphoma.

Symptoms are variable but can include: swollen lymph glands, fevers, night sweats, fatigue, unexplained weight loss, pain or abdominal bloating, chest pain, cough, difficulty breathing. Diagnosis may include physical exam of the lymph nodes, spleen and liver, blood tests, x-rays, scans, and finally a biopsy from lymph tissue. The treatment and prognosis or outlook depends upon the specific type of B-cell lymphoma and other factors present but often includes radiation, chemotherapy and medications. Speak with your physician for the most current treatment options. Support groups are also a great resource for support and information and can help connect you to other individuals with B-cell lymphoma.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "B-Cell Lymphomas" returned 557 free, full-text research articles on human participants. First 3 results:

High 18F-fluorodeoxyglucose uptake in primary bilateral adrenal diffuse large B-cell lymphomas with nongerminal center B-cell phenotype: A case report.
 

Author(s): Jing Zhou, Yigang Zhao, Zhengxing Gou

Journal: Medicine (Baltimore). 2018 Apr;97(17):e0480.

 

Bilateral adrenal diffuse large B-cell lymphoma, nongerminal center B-cell phenotype (non-GCB DLBCL), is an uncommon malignancy that exhibits rapid development. Fluorine-18-fluorodeoxyglucose position emission tomography/computed tomography (CT) is extremely sensitive in distinguishing ...

Last Updated: 31 Dec 1969

Go To URL
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study.
 

Author(s): Amrita Goyal, Joi B Carter, Itai Pashtan, Sara Gallotto, Irene Wang, Scott Isom, Andrea Ng, Karen M Winkfield

Journal: J. Am. Acad. Dermatol.. 2018 02;78(2):408-410.

 

Last Updated: 31 Dec 1969

Go To URL
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
 

Author(s): Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg, Mariusz Wasik, Bruce L Levine, Simon F Lacey, Jan J Melenhorst, David L Porter, Carl H June

Journal: N. Engl. J. Med.. 2017 12;377(26):2545-2554.

 

Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "B-Cell Lymphomas" returned 52 free, full-text review articles on human participants. First 3 results:

Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification.
 

Author(s): Anna Szumera-Ciećkiewicz, Grzegorz Rymkiewicz, Beata Grygalewicz, Dorota Jesionek-Kupnicka, Andrzej Gruchała, Bogna Ziarkiewicz-Wróblewska, Krystyna Gałązka, Joanna Reszeć, Katarzyna Borg, Monika Prochorec-Sobieszek

Journal: Pol J Pathol. ;69(1):1-19.

 

Revision of the fourth edition of the World Health Organisation (WHO) Classification of Haematopoietic and Lymphatic Tissues, which was published in 2017, introduced important changes updating the biology, pathology, genetics, and clinical presentation of aggressive B-cell lymphomas. ...

Last Updated: 31 Dec 1969

Go To URL
Current Progress in EBV-Associated B-Cell Lymphomas.
 

Author(s): Yonggang Pei, Alexandria E Lewis, Erle S Robertson

Journal: Adv. Exp. Med. Biol.. 2017 ;1018():57-74.

 

Epstein-Barr virus (EBV) was the first human tumor virus discovered more than 50 years ago. EBV-associated lymphomagenesis is still a significant viral-associated disease as it involves a diverse range of pathologies, especially B-cell lymphomas. Recent development of high-throughput ...

Last Updated: 31 Dec 1969

Go To URL
New treatment for non-Hodgkin B-cell lymphomas with a special focus on the impact of junctional adhesion molecules.
 

Author(s): Beat Albert Imhof, Thomas Matthes

Journal:

 

Current therapeutic modalities used for B-cell lymphoma include chemotherapy, immunotherapy, and radiation therapy. Chemotherapy together with anti-CD20 monoclonal antibodies forms the cornerstone of therapy and has a curative, as well as a palliative, role in this disease. New treatment ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
 

Status: Recruiting

Condition Summary: B-cell Lymphoma

 

Last Updated: 6 Mar 2018

Go to URL
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
 

Status: Recruiting

Condition Summary: B Cell Lymphoma

 

Last Updated: 6 Feb 2018

Go to URL